Reported about 5 hours ago
Eli Lilly's recent announcement of a $27 billion investment in US manufacturing for GLP-1 weight-loss drugs, such as Mounjaro and Zepbound, is set to enhance domestic production and potentially ease tariff-related issues. Mizuho healthcare strategist Jared Holz highlights that this investment could help stabilize prices while maintaining the drugs’ significant health benefits beyond weight loss. He anticipates the possibility of a pill form of GLP-1s by 2027, emphasizing the medications' affordability relative to their extensive health advantages.
Source: YAHOO